Assessment of serum inflammatory parameters in RRMS and SPMS patients

References

• Adamczyk-Sowa M, Nowak-Kiczmer M, Jaroszewicz J, et al. Immunosenescence and multiple sclerosis. Neurol Neurochir Pol. 2022;56(3):220–227. doi: 10.5603/PJNNS.a2022.0045
   PubMed Web of Science ®Google Scholar
• McKay KA, Kwan V, Duggan T, et al. Risk factors associated with the onset of relapsing-remitting and primary progressive multiple sclerosis: a systematic review. Biomed Res Int. 2015;2015:817238. doi: 10.1155/2015/817238
   PubMed Web of Science ®Google Scholar
• Cree BAC, Arnold DL, Chataway J, et al. Secondary progressive multiple sclerosis: new insights. Neurology. 2021;97(8):378–388. doi: 10.1212/WNL.0000000000012323
   PubMed Web of Science ®Google Scholar
• Zeydan B, Kantarci OH. Impact of age on multiple sclerosis disease activity and progression. Curr Neurol Neurosci Rep. 2020;20(7):24. doi: 10.1007/s11910-020-01046-2
   PubMed Web of Science ®Google Scholar
• Ruiz F, Vigne S, Pot C. Resolution of inflammation during multiple sclerosis. Semin Immunopathol. 2019;41(6):711–726. doi: 10.1007/s00281-019-00765-0
   PubMed Web of Science ®Google Scholar
• Roe K. An inflammation classification system using cytokine parameters. Scand J Immunol. 2021;93(2):e12970. doi: 10.1111/sji.12970
   PubMed Web of Science ®Google Scholar
• Sonar S, Lal G. Role of tumor necrosis factor superfamily in neuroinflammation and autoimmunity. Front Immunol. 2015;6:364. doi: 10.3389/fimmu.2015.00364
   PubMed Web of Science ®Google Scholar
• Capobianchi MR, Uleri E, Caglioti C, et al. Type I IFN family members: similarity, differences and interaction. Cytokine Growth Factor Rev. 2015;26(2):103–111. doi: 10.1016/j.cytogfr.2014.10.011
   PubMed Web of Science ®Google Scholar
• Vignali DAA, Collison LW, Workman CJ. How regulatory T cells work. Nat Rev Immunol. 2008;8(7):523–532. doi: 10.1038/nri2343
   PubMed Web of Science ®Google Scholar
• Balasa R, Bianca C, Septimiu V, et al. The matrix metalloproteinases panel in multiple sclerosis patients treated with Natalizumab: a possible answer to Natalizumab non- responders. CNS Neurol Disord Drug Targets. 2018;17(6):464–472. doi: 10.2174/1871527317666180703102536
   PubMed Web of Science ®Google Scholar
• Grudzińska E, Grzegorczyn S, Czuba ZP. Chemokines and growth factors produced by lymphocytes in the incompetent great saphenous vein. Mediators Inflamm. 2019;2019:7057303. doi: 10.1155/2019/7057303
   PubMed Web of Science ®Google Scholar
• Lejawa M, Osadnik K, Czuba Z, et al. Association of metabolically healthy and unhealthy obesity phenotype with markers related to obesity, diabetes among young, healthy adult men. Analysis of MAGNETIC study. Life (Basel). 2021;11(12):11. doi: 10.3390/life11121350
   Web of Science ®Google Scholar
• Idzik M, Poloczek J, Skrzep-Poloczek B, et al. The effects of 21-day general rehabilitation after hip or knee surgical implantation on plasma levels of selected Interleukins, VEGF, TNF-α, PDGF-BB, and eotaxin-1. Biomolecules. 2022;12(5):12. doi: 10.3390/biom12050605
   Web of Science ®Google Scholar
• Piazza F, DiFrancesco JC, Fusco ML, et al. Cerebrospinal fluid levels of BAFF and APRIL in untreated multiple sclerosis. J Neuroimmunol. 2010;220(1–2):104–107. doi: 10.1016/j.jneuroim.2010.01.011
   PubMed Web of Science ®Google Scholar
• Wang H, Wang K, Zhong X, et al. Cerebrospinal fluid BAFF and APRIL levels in neuromyelitis optica and multiple sclerosis patients during relapse. J Clin Immunol. 2012;32(5):1007–1011. doi: 10.1007/s10875-012-9709-9
   PubMed Web of Science ®Google Scholar
• Braun T, Juenemann M, Dornes K, et al. BAFF serum and CSF levels in patients with multiple sclerosis and infectious nervous system diseases. Int J Neurosci. 2021;131(12):1231–1236. doi: 10.1080/00207454.2020.1784167
   PubMed Web of Science ®Google Scholar
• Puthenparampil M, Miante S, Federle L, et al. BAFF is decreased in the cerebrospinal fluid of multiple sclerosis at clinical onset. J Neuroimmunol. 2016;297:63–67. doi: 10.1016/j.jneuroim.2016.05.013
   PubMed Web of Science ®Google Scholar
• Ragheb S, Li Y, Simon K, et al. Multiple sclerosis: BAFF and CXCL13 in cerebrospinal fluid. Mult Scler. 2011;17(7):819–829. doi: 10.1177/1352458511398887
   PubMed Web of Science ®Google Scholar
• Magliozzi R, Marastoni D, Calabrese M. The BAFF/APRIL system as therapeutic target in multiple sclerosis. Expert Opin Ther Targets. 2020;24(11):1135–1145. doi: 10.1080/14728222.2020.1821647
   PubMed Web of Science ®Google Scholar
• Schmidt-Arras D, Rose-John S. IL-6 pathway in the liver: from physiopathology to therapy. J Hepatol. 2016;64(6):1403–1415. doi: 10.1016/j.jhep.2016.02.004
   PubMed Web of Science ®Google Scholar
• Garbers C, Aparicio-Siegmund S, Rose-John S. The IL-6/gp130/STAT3 signaling axis: recent advances towards specific inhibition. Curr Opin Immunol. 2015;34:75–82. doi: 10.1016/j.coi.2015.02.008
   PubMed Web of Science ®Google Scholar
• Rothaug M, Becker-Pauly C, Rose-John S. The role of interleukin-6 signaling in nervous tissue. Biochim Biophys Acta. 2016;1863(6):1218–1227. doi: 10.1016/j.bbamcr.2016.03.018
   PubMed Web of Science ®Google Scholar
• Taga T, Kishimoto T. Gp130 and the interleukin-6 family of cytokines. Annu Rev Immunol. 1997;15(1):797–819. doi: 10.1146/annurev.immunol.15.1.797
   PubMedGoogle Scholar
• Rose-John S. Interleukin-6 Family Cytokines. Cold Spring Harb Perspect Biol. 2018;10(2):10. doi: 10.1101/cshperspect.a028415
   Web of Science ®Google Scholar
• Gurfein BT, Zhang Y, Lopez CB, et al. IL-11 regulates autoimmune demyelination. J Immunol. 2009;183(7):4229–4240. doi: 10.4049/jimmunol.0900622
   PubMed Web of Science ®Google Scholar
• Maheshwari A, Janssens K, Bogie J, et al. Local overexpression of interleukin-11 in the central nervous system limits demyelination and enhances remyelination. Mediators Inflamm. 2013;2013:685317. doi: 10.1155/2013/685317
   PubMed Web of Science ®Google Scholar
• Padberg F, Feneberg W, Schmidt S, et al. CSF and serum levels of soluble interleukin-6 receptors (sIL-6R and sgp130), but not of interleukin-6 are altered in multiple sclerosis1Part of this work was presented in abstract form at the twenty-seventh annual meeting of the society for neuroscience, October 25–30, 1997, New Orleans, LA, USA.1. J Neuroimmunol. 1999;99(2):218–223. doi: 10.1016/S0165-5728(99)00120-4
   PubMedGoogle Scholar
• Amini R, Karampoor S, Zahednasab H, et al. Serum levels of matrix metalloproteinase-2, -9, and vitamin D in patients with multiple sclerosis with or without herpesvirus-6 seropositivity. Braz J Infect Dis. 2020;24(2):144–149. doi: 10.1016/j.bjid.2020.02.001
   PubMed Web of Science ®Google Scholar
• Benesová Y, Vasku A, Novotná H, et al. Matrix metalloproteinase-9 and matrix metalloproteinase-2 as biomarkers of various courses in multiple sclerosis. Mult Scler. 2009;15(3):316–322. doi: 10.1177/1352458508099482
   PubMed Web of Science ®Google Scholar
• Castellazzi M, Ligi D, Contaldi E, et al. Multiplex matrix metalloproteinases analysis in the cerebrospinal fluid reveals potential specific patterns in multiple sclerosis patients. Front Neurol. 2018;9:1080. doi: 10.3389/fneur.2018.01080
   PubMed Web of Science ®Google Scholar
• Galboiz Y, Shapiro S, Lahat N, et al. Matrix metalloproteinases and their tissue inhibitors as markers of disease subtype and response to interferon-β therapy in relapsing and secondary-progressive multiple sclerosis patients. Ann Neurol. 2001;50(4):443–451. doi: 10.1002/ana.1218
   PubMed Web of Science ®Google Scholar
• Rempe RG, Hartz AMS, Bauer B. Matrix metalloproteinases in the brain and blood–brain barrier: versatile breakers and makers. J Cereb Blood Flow Metab. 2016;36(9):1481–1507. doi: 10.1177/0271678X16655551
   PubMed Web of Science ®Google Scholar
• Niino M, Kikuchi S. Osteopontin and multiple sclerosis: An update. Clin Exp Immunol. 2011;2(2):33–40. doi: 10.1111/j.1759-1961.2011.00019.x
   Google Scholar
• Iaffaldano P, Ribatti D, Trojano M. Natalizumab reduces serum pro-angiogenic activity in MS patients. Neurol Sci. 2018;39(4):725–731. doi: 10.1007/s10072-018-3266-9
   PubMed Web of Science ®Google Scholar
• Orsi G, Cseh T, Hayden Z, et al. Microstructural and functional brain abnormalities in multiple sclerosis predicted by osteopontin and neurofilament light. Mult Scler Relat Disord. 2021;51:102923. doi: 10.1016/j.msard.2021.102923
   PubMed Web of Science ®Google Scholar
• Agah E, Zardoui A, Saghazadeh A, et al. Osteopontin (OPN) as a CSF and blood biomarker for multiple sclerosis: a systematic review and meta-analysis. PLoS One. 2018;13(1):e0190252. doi: 10.1371/journal.pone.0190252
   PubMed Web of Science ®Google Scholar
• Comabella M, Pericot I, Goertsches R, et al. Plasma osteopontin levels in multiple sclerosis. J Neuroimmunol. 2005;158(1–2):231–239. doi: 10.1016/j.jneuroim.2004.09.004
   PubMed Web of Science ®Google Scholar
• Gong L, Dong C, Cai Q, et al. Interleukin 32: a novel player in perioperative neurocognitive disorders. Med Hypotheses. 2020;144:110158. doi: 10.1016/j.mehy.2020.110158
   PubMed Web of Science ®Google Scholar
• Parray Z, Zargar MH, Asimi R, et al. Interleukin 32 gene promoter polymorphism: a genetic risk factor for multiple sclerosis in Kashmiri population. Gene. 2022;824:146261. doi: 10.1016/j.gene.2022.146261
   PubMed Web of Science ®Google Scholar
• Morsaljahan Z, Rafiei A, Valadan R, et al. Association between interleukin-32 polymorphism and multiple sclerosis. J Neurol Sci. 2017;379:144–150. doi: 10.1016/j.jns.2017.05.045
   PubMed Web of Science ®Google Scholar